Neurocrine Biosciences | NBIX - 売上総利益

株価
131.25
毎日の変更
3.13 2.44%
毎月
1.97%
毎年
21.88%
Q2 予測
124.95




売上総利益 変化する 日付
AbbVie USD 12.07B 1.59B 2025-12
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Agios Pharmaceuticals USD 18.09M 6.89M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Cytokinetics USD 17.76M 15.82M 2025-12
Enanta Pharmaceuticals -22.29M 23.75M 2024-12
Exelixis USD 572.18M 7M 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
Halozyme Therapeutics USD 281.77M 2.41M 2025-09
Incyte USD 1.17B 217.51M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Prothena USD 21K 2.39M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Repligen USD 103.83M 3.32M 2025-12
Rigel Pharmaceuticals USD 28.49M 7.01M 2024-06
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12
Xoma 992K 846K 2024-06